(Q34283690)

1 August 2017

title

Femoral insufficiency fractures associated with prolonged bisphosphonate therapy (English)

1 reference

1 August 2017

1 reference

Joseph D Isaacs

1

1 reference

1 August 2017

Louis Shidiak

series ordinal

2

1 reference

1 August 2017

Ian A Harris

series ordinal

3

1 reference

1 August 2017

Zoltan L Szomor

series ordinal

4

1 reference

1 August 2017

language of work or name

English

0 references

publication date

31 August 2010

1 reference

Clinical Orthopaedics and Related Research

1 August 2017

published in

1 reference

1 August 2017

volume

468

1 reference

1 August 2017

issue

12

1 reference

1 August 2017

page(s)

3384-3392

1 reference

https://scigraph.springernature.com/pub.10.1007/s11999-010-1535-x

1 August 2017

exact match

0 references

cites work

Parathyroid hormone and bisphosphonate have opposite effects on stress fracture repair

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2974861

Femoral cortical stress lesions in long-term bisphosphonate therapy: a herald of impending fracture?

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2974861

Collagen cross-links as a determinant of bone quality: a possible explanation for bone fragility in aging, osteoporosis, and diabetes mellitus

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2974861

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2974861

Influence of remodeling on the mineralization of bone tissue.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2974861

Case reports: two femoral insufficiency fractures after long-term alendronate therapy

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2974861

Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2974861

Changes in non-enzymatic glycation and its association with altered mechanical properties following 1-year treatment with risedronate or alendronate.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2974861

Severely suppressed bone turnover and atypical skeletal fragility

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2974861

Risk of hip fracture after bisphosphonate discontinuation: implications for a drug holiday

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2974861

Low-energy femoral shaft fractures associated with alendronate use.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2974861

An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy?

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2974861

Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2974861

Insights into material and structural basis of bone fragility from diseases associated with fractures: how determinants of the biomechanical properties of bone are compromised by disease.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2974861

Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2974861

Efficacy and safety of oral alendronate treatment in children and adolescents with osteoporosis.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2974861

Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2974861

Severely suppressed bone turnover: a potential complication of alendronate therapy

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2974861

Meta-analysis of the efficacy of alendronate for the prevention of hip fractures in postmenopausal women

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2974861

The upper GI safety and tolerability of oral alendronate at a dose of 70 milligrams once weekly: a placebo-controlled endoscopy study

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2974861

Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2974861

Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2974861

Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2974861

Upper gastrointestinal tract safety profile of alendronate: the fracture intervention trial

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2974861

Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2974861

Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2974861

Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2974861

Treatment of postmenopausal osteoporosis with slow-release sodium fluoride. Final report of a randomized controlled trial.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2974861

Treatment of postmenopausal osteoporosis with transdermal estrogen

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2974861

Aging of microstructural compartments in human compact bone

6 July 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11999-010-1535-X

Three years of alendronate treatment results in similar levels of vertebral microdamage as after one year of treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11999-010-1535-X

Alterations in canine vertebral bone turnover, microdamage accumulation, and biomechanical properties following 1-year treatment with clinical treatment doses of risedronate or alendronate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11999-010-1535-X

Design of the Fracture Intervention Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11999-010-1535-X

Changes in bone remodeling rate influence the degree of mineralization of bone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11999-010-1535-X

Ten years' experience with alendronate for osteoporosis in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11999-010-1535-X

Bilateral low-energy simultaneous or sequential femoral fractures in patients on long-term alendronate therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11999-010-1535-X

Effects of vertebral bone fragility and bone formation rate on the mineralization levels of cancellous bone from white females

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11999-010-1535-X

Teriparatide reduces bone microdamage accumulation in postmenopausal women previously treated with alendronate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11999-010-1535-X

Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11999-010-1535-X

Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11999-010-1535-X

Bisphosphonate treatment suppresses not only stochastic remodeling but also the targeted repair of microdamage

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11999-010-1535-X

Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11999-010-1535-X

Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11999-010-1535-X

Alendronate increases degree and uniformity of mineralization in cancellous bone and decreases the porosity in cortical bone of osteoporotic women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11999-010-1535-X

Subtrochanteric displaced insufficiency fracture after long-term alendronate therapy--a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11999-010-1535-X

Bisphosphonate-induced osteopetrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11999-010-1535-X

Atraumatic bilateral femur fracture in long-term bisphosphonate use.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2974861

Alendronate for the Treatment of Osteoporosis in Men

28 October 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11999-010-1535-X

Multinational, Placebo-Controlled, Randomized Trial of the Effects of Alendronate on Bone Density and Fracture Risk in Postmenopausal Women with Low Bone Mass: Results of the FOSIT Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11999-010-1535-X

Increments in Bone Mineral Density of the Lumbar Spine and Hip and Suppression of Bone Turnover Are Maintained after Discontinuation of Alendronate in Postmenopausal Women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11999-010-1535-X

Long-term safety of bisphosphonates

21 January 2018

1 reference

12 December 2020

Should bisphosphonates be continued indefinitely? An unusual fracture in a healthy woman on long-term alendronate

1 reference

12 December 2020

Bisphosphonate-induced fractures: nature strikes back?

1 reference

12 December 2020

Skeletal accumulation of bisphosphonates: implications for osteoporosis treatment

1 reference

12 December 2020

Teriparatide following bisphosphonates: initial and long-term effects on microarchitecture and bone remodeling at the human iliac crest

1 reference

12 December 2020

Bisphosphonates and low-impact femoral fractures: current evidence on alendronate-fracture risk

1 reference

12 December 2020

Bisphosphonate-associated femoral fracture: implications for management in patients with malignancies

1 reference

12 December 2020

Non-traumatic fracture of the femoral shaft in a patient taking long-term bisphosphonate therapy

1 reference

12 December 2020

Prophylactic bilateral intramedullary femoral nails for bisphosphonate-associated signs of impending subtrochanteric hip fracture

1 reference

12 December 2020

Does suppression of bone turnover impair mechanical properties by allowing microdamage accumulation?

1 reference

12 December 2020

Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. Phase III Osteoporosis Treatment Study Group

1 reference

12 December 2020

Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women

1 reference

12 December 2020

Long-term treatment of incadronate disodium accumulates microdamage but improves the trabecular bone microarchitecture in dog vertebra

1 reference

12 December 2020

Suppressed bone turnover by long-term bisphosphonate treatment accumulates microdamage but maintains intrinsic material properties in cortical bone of dog rib

1 reference

12 December 2020

Effects of differences in mineralization on the mechanical properties of bone

1 reference

12 December 2020

Intermittent cyclical etidronate treatment of postmenopausal osteoporosis

1 reference

12 December 2020

Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment

1 reference

12 December 2020

Long-term effects of a treatment course with oral alendronate of postmenopausal osteoporosis

1 reference

12 December 2020

10.1007/S11999-010-1535-X

Identifiers

DOI

1 reference

Dimensions Publication ID

1 August 2017

1019788188

0 references

Fatcat ID

release_7u5emrxvx5cednetefnb6wh2i4

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/7u5emrxvx5cednetefnb6wh2i4

24 November 2022

mapped directly with Wikidata item

PMC publication ID

2974861

1 reference

1 August 2017

1 reference